Literature DB >> 24163076

Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity.

Rajamma Mathew1.   

Abstract

Pulmonary hypertension (PH) is a progressive disease with a high morbidity and mortality rate. Despite important advances in the field, the precise mechanisms leading to PH are not yet understood. Main features of PH are loss of vasodilatory response, the activation of proliferative and antiapoptotic pathways leading to pulmonary vascular remodeling and obstruction, elevated pressure and right ventricular hypertrophy, resulting in right ventricular failure and death. Experimental studies suggest that endothelial dysfunction may be the key underlying feature in PH. Caveolin-1, a major protein constituent of caveolae, interacts with several signaling molecules including the ones implicated in PH and modulates them. Disruption and progressive loss of endothelial caveolin-1 with reciprocal activation of proliferative pathways occur before the onset of PH, and the rescue of caveolin-1 inhibits proliferative pathways and attenuates PH. Extensive endothelial damage/loss occurs during the progression of the disease with subsequent enhanced expression of caveolin-1 in smooth muscle cells. This caveolin-1 in smooth muscle cells switches from being an antiproliferative factor to a proproliferative one and participates in cell proliferation and cell migration, possibly leading to irreversible PH. In contrast, the disruption of endothelial caveolin-1 is not observed in the hypoxia-induced PH, a reversible form of PH. However, proliferative pathways are activated in this model, indicating caveolin-1 dysfunction. Thus disruption or dysfunction of endothelial caveolin-1 leads to PH, and the status of caveolin-1 may determine the reversibility versus irreversibility of PH. This article reviews the role of caveolin-1 and cell membrane integrity in the pathogenesis and progression of PH.

Entities:  

Keywords:  caveolin-1; endothelial cells; pulmonary hypertension; smooth muscle cells

Mesh:

Substances:

Year:  2013        PMID: 24163076     DOI: 10.1152/ajpheart.00266.2013

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  20 in total

1.  Enhanced caveolin-1 expression in smooth muscle cells: Possible prelude to neointima formation.

Authors:  Jing Huang; John H Wolk; Michael H Gewitz; James E Loyd; James West; Eric D Austin; Rajamma Mathew
Journal:  World J Cardiol       Date:  2015-10-26

2.  Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice.

Authors:  Jason M Aliotta; Mandy Pereira; Sicheng Wen; Mark S Dooner; Michael Del Tatto; Elaine Papa; Laura R Goldberg; Grayson L Baird; Corey E Ventetuolo; Peter J Quesenberry; James R Klinger
Journal:  Cardiovasc Res       Date:  2016-03-14       Impact factor: 10.787

3.  Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension.

Authors:  Salina Gairhe; Keytam S Awad; Edward J Dougherty; Gabriela A Ferreyra; Shuibang Wang; Zu-Xi Yu; Kazuyo Takeda; Cumhur Y Demirkale; Parizad Torabi-Parizi; Eric D Austin; Jason M Elinoff; Robert L Danner
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-16       Impact factor: 11.205

Review 4.  Central Role of Metabolism in Endothelial Cell Function and Vascular Disease.

Authors:  Laura Bierhansl; Lena-Christin Conradi; Lucas Treps; Mieke Dewerchin; Peter Carmeliet
Journal:  Physiology (Bethesda)       Date:  2017-03

5.  Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.

Authors:  Yu-Cai Chen; Tian-Yi Yuan; Hui-Fang Zhang; Dan-Shu Wang; Yu Yan; Zi-Ran Niu; Yi-Huang Lin; Lian-Hua Fang; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2016-05-16       Impact factor: 6.150

Review 6.  Pulmonary hypertension and metabolic syndrome: Possible connection, PPARγ and Caveolin-1.

Authors:  Rajamma Mathew
Journal:  World J Cardiol       Date:  2014-08-26

7.  Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species.

Authors:  Feng Chen; Scott Barman; Yanfang Yu; Steven Haigh; Yusi Wang; Stephen M Black; Ruslan Rafikov; Huijuan Dou; Zsolt Bagi; Weihong Han; Yunchao Su; David J R Fulton
Journal:  Free Radic Biol Med       Date:  2014-05-14       Impact factor: 7.376

Review 8.  Hematological disorders and pulmonary hypertension.

Authors:  Rajamma Mathew; Jing Huang; Joseph M Wu; John T Fallon; Michael H Gewitz
Journal:  World J Cardiol       Date:  2016-12-26

9.  Rare variants in RNF213, a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxia-induced pulmonary hypertension in mice.

Authors:  Hatasu Kobayashi; Risako Kabata; Hideyuki Kinoshita; Takaaki Morimoto; Koh Ono; Midori Takeda; Jungmi Choi; Hiroko Okuda; Wanyang Liu; Kouji H Harada; Takeshi Kimura; Shohab Youssefian; Akio Koizumi
Journal:  Pulm Circ       Date:  2018-05-02       Impact factor: 3.017

10.  Caveolae protect endothelial cells from membrane rupture during increased cardiac output.

Authors:  Jade P X Cheng; Carolina Mendoza-Topaz; Gillian Howard; Jessica Chadwick; Elena Shvets; Andrew S Cowburn; Benjamin J Dunmore; Alexi Crosby; Nicholas W Morrell; Benjamin J Nichols
Journal:  J Cell Biol       Date:  2015-10-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.